Sarepta Files 8-K on Operations & Financial Condition
Ticker: SRPT · Form: 8-K · Filed: Jan 8, 2024 · CIK: 873303
Complexity: simple
Sentiment: neutral
Topics: financial-condition, operations, regulation-fd
TL;DR
**Sarepta just dropped an 8-K with financial updates, so keep an eye on their performance.**
AI Summary
Sarepta Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing updated financial information, which is crucial for investors to understand its current performance and future outlook. For shareholders, this matters because it offers transparency into the company's financial health, potentially influencing stock valuation and investment decisions.
Why It Matters
This filing provides investors with the latest financial and operational updates from Sarepta Therapeutics, which can impact their assessment of the company's value and future prospects.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently present new risks, but rather provides data for investors to assess existing risks.
Analyst Insight
A smart investor would review the detailed financial information and operational results that Sarepta Therapeutics, Inc. will disclose in connection with this 8-K to understand the company's current performance and future outlook.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 08, 2024 (date) — date of earliest event reported
- 001-14895 (string) — Commission File Number
- 93-0797222 (string) — IRS Employer Identification No.
- Delaware (string) — State of Incorporation
- 215 First Street, Cambridge, Massachusetts, 02142 (string) — Address of Principal Executive Offices
- (617) 274-4000 (string) — Registrant's Telephone Number
FAQ
What is the purpose of Sarepta Therapeutics, Inc.'s 8-K filing on January 8, 2024?
The 8-K filing by Sarepta Therapeutics, Inc. on January 8, 2024, is to report on its results of operations and financial condition, and to make a Regulation FD Disclosure, as indicated by the 'ITEM INFORMATION' sections.
What is the earliest event reported date for this 8-K filing?
The earliest event reported date for this 8-K filing is January 08, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
Where are Sarepta Therapeutics, Inc.'s principal executive offices located?
Sarepta Therapeutics, Inc.'s principal executive offices are located at 215 First Street, Cambridge, Massachusetts, 02142, according to the 'Address of Principal Executive Offices' section.
What is the Commission File Number for Sarepta Therapeutics, Inc.?
The Commission File Number for Sarepta Therapeutics, Inc. is 001-14895, as listed in the filing.
Under which sections of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as indicated in the header of the Form 8-K.
Filing Stats: 986 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2024-01-08 12:08:07
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT Nasdaq Glo
- $1.7 billion — audited) cash position of approximately $1.7 billion as of December 31, 2023, and that the C
- $1.145 billion — hat the Company generated approximately $1.145 billion in total net product revenue (unaudited
- $234.3 million — ucts, which includes: (i) approximately $234.3 million in net product revenue (unaudited) in t
- $945.0 million — ded December 31, 2023 and approximately $945.0 million in net product revenue (unaudited) in t
- $131.3 million — rsen) Injection, and (ii) approximately $131.3 million in net product revenue (unaudited) in t
- $200.4 million — ded December 31, 2023 and approximately $200.4 million in net product revenue (unaudited) in t
Filing Documents
- srpt-20240108.htm (8-K) — 46KB
- srpt-ex99_1.htm (EX-99.1) — 72KB
- 0000950170-24-002822.txt ( ) — 238KB
- srpt-20240108.xsd (EX-101.SCH) — 23KB
- srpt-20240108_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, Inc. (the “Company”) disclosed certain preliminary financial information for the year ended December 31, 2023 during the Company’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference (the “Conference”) and in discussions with third parties at the Conference. Specifically, the Company disclosed its (unaudited) cash position of approximately $1.7 billion as of December 31, 2023, and that the Company generated approximately $1.145 billion in total net product revenue (unaudited) in the year ended December 31, 2023 from sales of the Company’s four approved products, which includes: (i) approximately $234.3 million in net product revenue (unaudited) in the fourth quarter ended December 31, 2023 and approximately $945.0 million in net product revenue (unaudited) in the year ended December 31, 2023, each from sales of EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection, and (ii) approximately $131.3 million in net product revenue (unaudited) in the fourth quarter ended December 31, 2023 and approximately $200.4 million in net product revenue (unaudited) in the year ended December 31, 2023, each from sales of ELEVIDYS. The information in this Item 2.02 is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2023 and its results of operations for the three months and year ended December 31, 2023. The audit of the Company’s financial statements for the year ended December 31, 2023 is ongoing and could result in changes to the information in this Item 2.02.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01. On January 8, 2024, the Company issued a press release disclosing such information. A copy of the press release is furnished with this report as Exhibit 99.1. The information in this report, including Exhibit 99.1 attached hereto, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.
Forward-Looking Statements
Forward-Looking Statements This Current Report contains forward looking statements. Any statements contained in this Current Report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the Company's expected financial results. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the estimates and judgments the Company makes, or the assumptions on which it relies, in preparing its consolidated financial statements could prove inaccurate; the Company's revenues and operating results could fluctuate significantly, which may adversely affect the Company's stock price; and those risks identified under the heading “Risk Factors” in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 as well as other SEC filings made by the Company which you are encouraged to review.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 8, 2024 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: January 8, 2024 By: /s/ Douglas S. Ingram Douglas S. Ingram President and Chief Executive Officer